How Does Melanoma Subtype Influence Cutaneous Immune-Related Adverse Events in Patients Who Use ICI Therapy?
Source: Consultant 360, March 2023
In a recent retrospective multi-institutional cohort study1, researchers found that the presence of cutaneous immune-related adverse events (cirAEs) was associated with better survival among patients receiving immune checkpoint inhibitor (ICI) therapy.
Although previous study results2,3 have confirmed an association between cirAEs and improved survival among those with advanced melanoma treated with ICI therapy, researchers have yet to investigate the role of melanoma subtypes on cirAEs and whether there are any “downstream therapeutic outcomes."
Enter Nguyen and colleagues, whose study objective was to determine the impact of melanoma subtypes on cirAEs and survival among those who received ICI inhibitor therapy.